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Background: To conduct a comparative analysis of indicators of 
life quality and social functioning in patients with schizophrenia ac-
cording to the received treatment.
Materials and methods: The study involved 105 patients with par-
anoid schizophrenia between 18 and 55 years, who were randomly 
assigned to 3 groups. The first group included 35 patients treated 
with sertindole (average therapeutic dose of 18,0 cu chlorpromazine 
equivalents), the second – 35 patients treated with zuclopenthixol 
(4,0 arbitrary units), and a third – 35 patients treated with clozapine 
(2,0 contingent units). The rehabilitation included individual therapy 
compliance. All patients signed informed consent to participate in 
the study.
The study included the use of outpatient and inpatient patient 
cards and a questionnaire for the assessment of life quality and social 
functioning of the psychic patients.
Statistical data processing was carried out using the software 
package «Statistica 6.0».
Results: Summarizing the results, we can conclude a significance 
of the subjective assessment of the life quality in the responses of 
patients with schizophrenia to questions during a questionnaire for 
determining the level of life quality and social functioning.
In the study of the variability of indicators of life quality and social 
functioning of patients with schizophrenia, depending on the treat-
ment, all parameters throughout the course of therapy were higher in 
the group of patients treated with sertindole.
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Conclusion: Thus, sertindole is the drug of choice for long-term 
outpatient treatment of patients with schizophrenia, particularly in 
combination with compliance – therapy.
Keywords: life quality; schizophrenia; neuroleptics.
Schizophrenia is the disease that is characterized by the variety 
of clinical manifestations, which may cause difficulties in selecting 
a particular antipsychotic drug as the most appropriate treatment for 
each case [1].
Currently, the main medical problem after the manifestation and 
relief of acute symptoms of psychosis is the prevention of its’ re-
currence. The basic method of preventing relapse of schizophrenia 
symptoms is supporting neuroleptic drug therapy. Prevention and 
anti-treatment are the most important components of the community 
treatment [6].
Nowadays, when the traditional clinical approach no longer meets 
the needs of psychiatry, studying of the medical treatment of schizo-
phrenia due to «pharmacological resocialization ensure» will conform 
to modern principles of rehabilitation treatment, which goal is not 
only the elimination of psychopathology, but also the achievement of 
acceptable social functioning and life quality level of the patients [6].
In addition to the psychopathological symptoms reduction the re-
searchers considered the social functioning and life quality improve-
ment of the patients as the indicators of treatment and rehabilitation 
effectiveness. This fact is very important for therapeutic measures in 
neuropsychiatric clinics [11].
An important criterion for assessment of social functioning and ad-
aptation is life quality. Regarding patients with schizophrenia it can 
be determined as a measure integrating a large number of physical, 
psychological, emotional and social characteristics, demonstrating 
person’s ability to adapt to the manifestations of the disease, which is 
impaired in patients with schizophrenia because of the cognitive and 
affective components [9].
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Life quality is defined by the WHO as «the individuals’ perception 
of their position in life in the context of its’ culture and value systems 
in relation to their goals, expectations, standards and concerns». Over 
the past two decades there is a growing interest to the life quality of 
patients with schizophrenia, as schizophrenia is the progressive disor-
der that leads to severe social and occupational dysfunction. Besides 
the appearance of atypical antipsychotics with higher efficiency and 
lower risks of extrapyramidal side effects, compared to typical, caused 
the increased interest to patients with schizophrenia. Life quality mea-
surement is based on the medical care and intervention principles, 
taking into account the patient’s opinion during the diagnostics and 
the development of the treatment algorithm. Nevertheless, there are 
still doubts whether the patients are able to independent assessment of 
their life quality due to the cognitive deficits and criticism violations 
[13]. Lehman et al. demonstrated an integrative approach to the per-
ception of life quality between patients and physicians with the rec-
ommendations of being careful to the scores reliability made by severe 
psychic patients [17]. Browne et al. summarized the opinion of several 
authors and stated that the clinical assessment of life quality obtained 
from the reports of psychiatric hospital patients is advantageous, since 
their self-esteem may be influenced by the psychotic symptoms, pecu-
liar attitudes and values  of these patients [14]. Skantze et al. showed 
that patients with schizophrenia are able to communicate about their 
social deficits which supports the view that life quality can be assessed 
subjectively [19]. Lehman proved the ability to collect statistically 
significant data about life quality of patients with mental illness and 
concluded that the subjective assessment of life quality can be applied 
to these patients [17]. However the reliability of patient’s life quality 
self-assessment should be discussed in the clinical practice to inform 
them about all aspects of treatment and assistance services [13].
In modern pharmacotherapy of patients with schizophrenia the 
studying of methods of life quality assessment plays an important role. 
Currently, the indicators of patients’ life quality, obtained through a 
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variety of measuring instruments are described or analyzed in the 
majority of scientific publications devoted to the clinical efficacy of 
drugs for the schizophrenia treatment. Although there are different 
specific ways to measure the patients’ life quality, none of them take 
into account the factor of drug exposure. At the same time, there is 
a significant amount of research devoted to the influence of certain 
antipsychotic drugs to the life quality indicators in schizophrenia pa-
tients. The results of a number comparative studies indicate the higher 
life quality in patients receiving various atypical antipsychotics than 
in patients received conventional therapy. The results of these studies 
suggest that the antipsychotic drugs may influence the life quality of 
patients with schizophrenia [7].
The problem of social functioning and life quality of patients is one 
of the most urgent problems of modern psychiatry [4].
Great prospects to improving of life quality are associated with the 
ability of atypical neuroleptics to reduce negative manifestations, in-
cluding emotional deficiency, which would contribute to a certain de-
gree of cognitive function normalization [10]. EUFEST study (Euro-
pean First Episode Schizophrenia Trial) has confirmed the benefits of 
atypical antipsychotics (quetiapine and amisulpride) in the treatment 
of patients with schizophrenia. The cancel and tolerability coefficients 
of these drugs were significantly better in comparison with low doses 
of haloperidol [5].
It is believed that the use of atypical antipsychotics may not only 
improve the efficiency and safety of treatment in the short term, but 
also leads to increased patients’ therapy compliance, which helps to 
reduce the frequency and length of hospitalizations. This will decrease 
the indirect costs associated with premature disability of employable 
patients and the forced termination of their relatives’ employment con-
nected with such issues as auto - and hetero- aggression [12].
The researchers found the differences in the subjective assessments 
of the life quality of patients with schizophrenia receiving conventional 
antipsychotics or atypical antipsychotics. In general, at the stage of drug 
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remission the researchers marked the most consistently high subjective 
quality of life in the area of social and legal status (kernel module). 
The most consistently poor performance (poor life quality) was found 
in patients with schizophrenia in the spiritual realm (specific unit) and 
the psychological sphere. At the same time, the received pharmacother-
apy has the importance. Thus, the authors emphasize the significantly 
higher subjective indicators of life quality in sub spheres of «Mental life 
quality» and «Peculiarities of sexual intercourse» in patients receiving 
atypical antipsychotics compared with those receiving traditional phar-
macy [10]. The numerous papers devoted to the study of the life quality 
of patients with schizophrenia demonstrate the dependence of subjec-
tive life quality on the many factors that can be combined into three 
main groups: psychosocial, medical and procedural factors. The impact 
of these factors on changes in the life quality individual indicators of 
patients with schizophrenia may explain 12 to 36% of the variance [8].
One of the methods adopted for the evaluation of life quality is the 
studying of quality-adjusted life-year-QALY [16]. In the comparative 
study devoted to the sertindole therapy versus risperidone, olanzapine 
and aripiprazole the efficiency was defined as the duration of the pe-
riod without relapse over a five-year period and the QALY. According 
to this study, the duration of the period without exacerbations and the 
QALY in sertindole group were comparable to the comparators [18].
Numerous foreign studies of pharmacoeconomic sertindole effec-
tiveness, based on the results of a prospective, randomized and con-
trolled clinical trials have shown that the use of this drug is cost-effec-
tive not only because of the relapses frequency and readmissions re-
ducing of patients with schizophrenia, but also because of their social 
functioning and life quality improving [15].
However, there is no drug that could meet the needs of all patients. 
Each new antipsychotic may provide additional treatment options, in 
case when doctors are aimed to treating patients with schizophrenia 
not only for symptoms relief, but also to restore the proper level of 
social functioning [7].
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In this context the goal of the research was to conduct the compar-
ative analysis of the patients with schizophrenia life quality and social 
functioning indicators, depending on the received treatment.
The research was conducted from 2015 at the psychiatry, narcol-
ogy, psychotherapy and clinical psychology department of Saratov 
State Medical University n.a V.I. Razumovsky and in the Regional 
Clinical Psychiatric Hospital of St. Sophia.
The 105 patients with paranoid schizophrenia from 18 to 55 years 
(mean age 35,8±1,4 years, 62 women, 43 men) were included in the 
study. The acute psychotic symptoms at the therapy beginning, ex-
pressed personality defect and severe somatic pathology absence were 
the inclusion criteria. Patients were randomized according to the table 
prepared by using a computer method for random numbers generating. 
Thereunder the patients were administered one or another studied anti-
psychotics. Thus, the patients were randomly divided into three groups. 
The group 1 consisted of 35 patients who were appointed to treatment 
with sertindole, the 2nd group consisted of 35 patients treated with zu-
clopenthixol and the 3d one included 35 patients treated with clozapine. 
All subjects received study medication in secondary therapeutic doses. 
The doses were calculated respectively chlorpromazine equivalent. So 
the dose of sertindole was 18,0 conventional units, zuclopenthixol – 4,0 
cu, clozapine – 2,0 cu. The rehabilitation approach was the individual 
compliance therapy. According to several studies the method of com-
pliance therapy showed a fairly high efficacy in patients with schizo-
phrenia by direct assessment. The further studying of this method on the 
various factors of compliance for a more complete and comprehensive 
study of long-term treatment outcomes and a better understanding of 
mechanisms of action remains actual [2].
All patients wrote the informed consent to participate in the study. 
There were 95% of patients fully completed the treatment (1 patient 
did not complete the study due to another city moving).
A survey of patients was carried out in five stages within 1 year: 
at admission, before discharge from the hospital (2 months after the 
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beginning of treatment), and ambulatory at 3, 6 months and one year 
after the discharge. During the treatment period the patients received a 
complex pathopsychological examination which included the assess-
ment of their clinical and psychopathological state in the dynamics. 
The scales and questionnaires were used for the data objectification. 
The research included the use of outpatient and inpatient medical re-
cords as well as the questionnaire for the assessment of social func-
tioning and life quality of the psychic patients [3]. In order to detect 
the statistically significant differences of the study results the compar-
ative analysis of 1 and 5 visits are represented on the figures.
The variation-statistical method of the conducted research results 
was the use of «Statistica» 6.0 application package using descriptive 
statistics, correlation and analysis of variance. We used the parametric 
features of a normal distribution and non-parametric methods, regard-
less of the type of distribution. The differences were considered statis-
tically significant at 95, 99 and 99.9% probability thresholds.
The analysis of the questionnaire for the assessment of the life 
quality and social functioning level results (LQ and SF) in patients 
with paranoid schizophrenia at the beginning and in the end of treat-
ment in all groups obtained such statistically significant indicators as 
the general well-being; health, food and clothing satisfaction; intellec-
tual productivity and contact with others.
The statistically significant differences in health, food and cloth-
ing satisfaction were obtained in sertindole and zuclopenthixol groups 
before treatment. Health satisfaction rate in sertindole group was 
2,92±0,11 whereas the same indicator in zuclopenthixol group made 
up 2,54±0,099 (p=0,023). Such mark as food satisfaction in sertindole 
group was equal to 3,53±0,08 and in zuclopenthixol group - 2,85±0,16 
(p=0,0005). Clothing satisfaction rate before treatment made up 
3,14±0,13 and 2,81±0,096 (p=0,02) in the both groups respectively.
During the similar analysis of the LQ and SF questionnaire results 
in patients with paranoid schizophrenia before treatment the statistical-
ly significant indicators were determined in such spheres as health and 
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food satisfaction in clozapine and sertindole groups. In the clozapine 
group the health satisfaction index was 2,53±0,12 (p=0,033) and the 
rate of food satisfaction in this group made up 2,63±0,16 (p=0,00002).
Such indicators as intellectual productivity, general well-being 
and contact with others before treatment in all treatment groups were 
statistically insignificant (p>0,05). Described data are represented at 
figure 1.
Fig. 1. The comparative dynamics of LQ and SF questionnaire results                                
before treatment
At the comparative analysis of similar indicators in patients with par-
anoid schizophrenia at the end of therapy in addition to health, food and 
clothing satisfaction the differences in general well-being, intellectual 
productivity and contact with others were also marked in the sertindole 
and zuclopenthixol groups. In sertindole group the general well-being 
was 3,11±0,1. In zuclopenthixol group it made up 2,73±0,1 (p=0,007). 
Health satisfaction in both groups was equal to 3,11±0,08 and 2,73±0,09 
(p=0,003) respectively. Such index as food satisfaction in sertindole 
group was 3,50±0,08 and in zuclopenthixol group it made up 2,85±0,16 
(p=0,0007). Clothing satisfaction at the end of treatment was 3,17±0,12 
and 2,85±0,09 (p=0,02) respectively in both groups. Intellectual pro-
ductivity in sertindole group made up 3,06±0,14 and in zuclopenthixol 
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group – 2.58±0,18 (p=0,026). The average score for contact with others 
was 3,19±0,13 and 2,88±0,13 (p=0,045) respectively.
At the end of the therapy (at visit 5) the statistically significant dif-
ferences in health, food and clothing satisfaction were determined in 
clozapine and sertindole groups. The dynamics of these parameters at 
the end of sertindole treatment was described earlier. As for clozapine 
group the health satisfaction rate made up 2,84±0,09 (p=0,035), food 
satisfaction was equal to 2,68±0,17 (p=0,0001) and clothing satisfac-
tion was 2,53±0,18 (p=0,003).
Fig. 2. The comparative dynamics of LQ and SF questionnaire results                              
before treatment
Summarizing the research results we can conclude the significance 
of the subjective component in the responses of patients with schizo-
phrenia while the questionnaire for the assessment of social function-
ing and life quality assessment. We may also say that the variability 
of the life quality and social functioning indicators in patients with 
schizophrenia depends on the treatment variant. Thus, all the parame-
ters throughout the therapy course were higher in the sertindole group. 
The received study results may suggest that sertindole is the drug of 
choice for the long-term outpatient schizophrenia treatment, especial-
ly in conjunction with compliance-therapy.
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